Comparison of intralesional 5-fluorouracil with MMR vaccine in warts
Not Applicable
- Conditions
- Health Condition 1: B079- Viral wart, unspecified
- Registration Number
- CTRI/2023/12/060907
- Lead Sponsor
- Department of Dermatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All consecutive patients having lesions of verruca vulgaris.
2. Patients between the ages of 14-60 years.
Exclusion Criteria
1. Pregnant or females planning for pregnancy or lactating mothers.
2. Immunocompromised individuals including HIV-AIDS.
3. Patients with known hypersensitivity to MMR vaccine or components of the vaccine (e.g. neomycin, gelatin) or 5-FU.
4. Patients having any significant systemic illness.
5. Patients having taken any vaccine in the last 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method